1Fedak PW,Verma S,Weisel RD,Li R.Cardiac remodelingand failure:from molecules to man (part Ⅰ-Ⅲ).Cardiovasc Pathol,2005,14:1-11
2Frigerio M,Roubina E.Drugs for left ventricular remodeling in heart failure.AmJ Cardiol,2005,96(12):10-18
3Kodama M,Tachikawa H,Kashimura T.Effectsof humoral factors on left ventricular remodeling under chronic heart failure.NipponYakurigakuZasshi,2004,123(2):63-70
4WongM,StaszewskyL,LatiniR,BarleraS,Glazer R,AknayN,HesterA,AnandI,CohnJN.Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure:ValsartanHeart Failure Trial (Val-HeFT) echocardiographic data.J Am CollCardio,12004,43:2022-2027
5López-Sendón J,Swedberg K,McMurray J,etal,for the Task Force onACE-inhibitors of the European Society of Carjiology.Expert consensus document on angiotens in converting ensymeinhibitorsincardiovasculardisease.EurHeartJ,2004,25:1454-1470
6Azizi M,Mé nard J.Combined blockade of the renin-angiotensin system with angiotensinconvertingenzymeinhibitorsandangiotensin Ⅱ type 1 receptor antagonists.Circulation,2004,109:2492 -2499
